It was recently reported that knockdown of ACAT1 expression in vivo using a viral vector alleviated AD-like pathology in a mouse model [277], confirming that ACAT1 and ACAT2 are both likely drug targets in AD and ATH. This evidence concerns the gene ACAT2 and Alzheimer disease.